# US 2020/0002387 A1 · Cd20-binding immunotoxins for inducing cellular internalization and methods using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002387 A1
- Document ID: US20200002387A1
- Status: Published application
- Kind: A1
- Application number: 16/568,638
- Filed: 2019-09-12
- Published: 2020-01-02
- Earliest claimed: 2013-03-12
- Assignees: Molecular Templates, Inc.
- Applicants: Molecular Templates, Inc.
- Inventors: Eric POMA; Erin WILLERT; Jason KIM; Jack HIGGINS; Sangeetha Rajagopalan
- Web page: https://patentgrep.com/patent/US20200002387A1

## CPC

- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07K 14/25: Shigella (G)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/245: Escherichia (G)
- C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K 16/20: from protozoa
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides CD20-binding proteins that bind to and rapidly internalize CD20 antigens from a cell surface location to the interior of a cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. Such additional materials may include peptides, antigens, enzymes, and polynucleotides. These CD20-binding proteins have uses in methods of internalizing themselves, targeted killing of CD20 expressing cells, delivering exogenous materials into CD20 expressing cells, and treating a variety of diseases involving CD20 expressing cells, such as cancers and immune disorders.

## Claims

### Claim 1

A CD20-binding protein comprising:
(a) a CD20 binding region comprising an immunoglobulin-type binding region that specifically binds an extracellular part of a CD20 polypeptide,
(b) a Shiga toxin A subunit effector polypeptide; and
(c) an additional exogenous material.

### Claim 2 (depends on 1)

The CD20-binding protein of claim 1, wherein the CD20-binding protein is capable of rapidly internalizing into a CD20-expressing cell within less than six hours when the CD20-binding protein is contacted with the CD20-expressing cell.

### Claim 3 (depends on 1)

The CD20-binding protein of claim 1, wherein the CD20-binding region comprises a complementary determining region 3 fragment, a constrained FR3-CDR3-FR4 polypeptide, a single-domain antibody fragment, a single-chain variable fragment, an antibody variable fragment, an antigen-binding fragment, an Fd fragment, a fibronectin-derived 10th fibronectin type III domain, a tenascin type III domain, ankyrin repeat motif domain, a low-density-lipoprotein-receptor-derived A-domain, a lipocalin, a Kunitz domain, a Protein-A-derived Z domain, a gamma-B crystallin-derived domain, a ubiquitin-derived domain, a Sac7d-derived polypeptide, a Fyn-derived SH2 domain, or any genetically manipulated counterparts of any of the foregoing that retain CD20 binding function.

### Claim 4 (depends on 1)

The CD20-binding protein of claim 1, wherein the Shiga toxin A subunit effector polypeptide comprises an amino acid sequence having at least 85% sequence identity to:
(i) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 25, or SEQ ID NO: 26;
(ii) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO: 26;
(iii) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO:
26; or
(iv) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO:
26.

### Claim 5 (depends on 1)

The CD20-binding protein of claim 1, wherein the CD20-binding region comprises:
(a) a heavy chain variable (VH) domain comprising an HCDR1 of SEQ ID NO: 6, an HCDR2 of SEQ ID NO: 7, and an HCDR3 of SEQ ID NO: 8, and a light chain variable (VL) domain comprising an LCDR1 of SEQ ID NO:9, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 11,
(b) a VH domain comprising an HCDR1 of SEQ ID NO: 21, an HCDR2 of SEQ ID NO: 22, and an HCDR3 of SEQ ID NO: 27, and a VL domain comprising an LCDR1 of SEQ ID NO: 24, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 11, or
(c) a VH domain comprising an HCDR1 of SEQ ID NO: 21, an HCDR2 of SEQ ID NO: 22, and an HCDR3 of SEQ ID NO: 23, and a VL domain comprising an LCDR1 of SEQ ID NO: 28, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 29.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the CD20-binding protein of claim 1 and at least one pharmaceutically acceptable excipient or carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, which comprises a solvate, salt, ester or amide of the CD20-binding protein.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the excipient is: acetate, alcohol, alpha-tocopherol, aluminum monostearate, ascorbic acid, ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorobutanol, citrate, cysteine hydrochloride, dextrose, ethanol, ethylenediaminetetraacetic acid, ethyloleate, gelatin, glycerine, glycerol, lactic acid, lecithin, mannitol, methyl parabens, monostearate salt, organic ester, paraben, phenol phosphate, phosphoric acid, polyalcohol, polyethylene glycol, polyol, propylene glycol, propylgallate, Ringer's solution, saline, sodium bisulfate, sodium bisulfite, sodium chloride, sodium metabisulfite, sodium sulfite, sorbic acid, sorbitol, sugar, tartaric acid, vegetable oil or water.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, which further comprises an acceptable solvent, vehicle, sterile aqueous solution, buffer, powder, sterile powder, surfactant, antioxidant, chelating agent, antimicrobial agent, preservative, isotonic agent, dispersion medium, coating, adjuvant, wetting agent, emulsifying agent, dispersing agent, adsorption delaying agent, stabilizer, or additive.

### Claim 10

A method for delivering an exogenous material into a CD20-expressing cell, the method comprising contacting a CD20-expressing cell having an interior with a CD20-binding protein comprising:
(a) a CD20 binding region comprising an immunoglobulin-type binding region and capable of specifically binding an extracellular part of a CD20 protein,
(b) a Shiga toxin A subunit effector polypeptide; and
(c) an additional exogenous material, and
wherein the contacting step results in the CD20-binding protein delivering the additional exogenous material into the interior of the CD20-expressing cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the CD20-binding region comprises: a complementary determining region 3 fragment, a constrained FR3-CDR3-FR4 polypeptide, a single-domain antibody fragment, a single-chain variable fragment, an antibody variable fragment, an antigen binding fragment, an Fd fragment, a fibronectin-derived 10th fibronectin type III domain, a tenascin type III domain, an ankyrin repeat motif domain, a low-density lipoprotein receptor-derived A domain, a lipocalin, a Kunitz domain, a Protein-A-derived Z domain, a gamma-B crystallin-derived domain, a ubiquitin-derived domain, a Sac7d-derived polypeptide, a Fyn-derived SH2 domain, or any genetically manipulated counterparts of any of the foregoing that retain CD20-binding function.

### Claim 12 (depends on 10)

The method of claim 10, wherein the contacting step results in the CD20-binding protein inducing cellular internalization of the CD20-binding protein in less than about an hour.

### Claim 13 (depends on 10)

The method of claim 10, wherein the Shiga toxin A subunit effector polypeptide comprises an amino acid sequence having at least 85% sequence identity to:
(i) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 25, or SEQ ID NO: 26;
(ii) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO: 26;
(iii) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO: 26, or
(iv) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 25 or SEQ ID NO: 26.

### Claim 14 (depends on 10)

The method of claim 10, wherein the CD20-binding region comprises:
(a) a heavy chain variable (VH) domain comprising an HCDR1 of SEQ ID NO: 6, an HCDR2 of SEQ ID NO: 7, and an HCDR3 of SEQ ID NO: 8, and a light chain variable (VL) domain comprising an LCDR1 of SEQ ID NO:9, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 11,
(b) a VH domain comprising an HCDR1 of SEQ ID NO: 21, an HCDR2 of SEQ ID NO: 22, and an HCDR3 of SEQ ID NO: 27, and a VL domain comprising an LCDR1 of SEQ ID NO: 24, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 11, or
(c) a VH domain comprising an HCDR1 of SEQ ID NO: 21, an HCDR2 of SEQ ID NO: 22, and an HCDR3 of SEQ ID NO: 23, and a VL domain comprising an LCDR1 of SEQ ID NO: 28, an LCDR2 of SEQ ID NO: 10, and an LDCR3 of SEQ ID NO: 29.
